Arecor Therapeutics

Arecor, a revenue-generating clinical-stage drug developer, has an in-house and partnered pipeline of enhanced products and portfolio of technology partnerships enabled by its proprietary formulation platform Arestat.

View More

AT278 ultra-concentrated insulin superior to benchmarks

Arecor Therapeutics | Update | 20 May 2024

View More

FY23 results evidence broader revenue base

Arecor Therapeutics | Lighthouse | 16 May2024

View More

Novel diabetes drug-device deal inked with Medtronic

Arecor Therapeutics | Lighthouse | 9 May2024

View More

TRx co-development deal centred on oral GLP-1 product

Arecor Therapeutics | Lighthouse | 13 March 2024

View More

New deals and first royalties to aid growth; key data H124

Arecor Therapeutics | Lighthouse | 1 February 2024

View More

Sanofi deal for INBRX-101 validates Arestat technology

Arecor Therapeutics | Lighthouse | 24 January 2024

View More

Second in-house Specialty Hospital deal

Arecor Therapeutics | Update | 7 December 2023

View More

Appreciating a well-executed development strategy

Arecor Therapeutics | Outlook | 30 November 2023

View More

AT220 European launch marks first Arestat success

Arecor Therapeutics | Lighthouse | 17 November 2023

View More
1 2 3